Distinct HLA associations by stroke subtype in children with sickle cell anemia

Blood

Volumn 101, Issue 7, 2003, Pages 2865-2869

  Hoppe, Carolyn ^a   Klitz, William ^b   Noble, Janelle ^b   Vigil, Lara ^b   Vichinsky, Elliott ^b   Styles, Lori ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAIN INFARCTION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENOTYPE; HLA SYSTEM; HLA TYPING; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SICKLE CELL ANEMIA; STROKE; ADOLESCENT; ALLELE; BRAIN; CEREBROVASCULAR ACCIDENT; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; GENE FREQUENCY; GENETICS; HISTOCOMPATIBILITY TEST; HOMOZYGOTE; IMMUNOLOGY; MULTICENTER STUDY; STATISTICAL ANALYSIS; VASCULARIZATION;

HLA ANTIGEN;

ADOLESCENT; ALLELES; ANEMIA, SICKLE CELL; BRAIN; CEREBROVASCULAR ACCIDENT; CHILD; DATA INTERPRETATION, STATISTICAL; GENE FREQUENCY; GENOTYPE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HOMOZYGOTE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY;

EID: 0038107362     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2791     Document Type: Article

References (32)

1. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103:640-645.
2. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
3. Pegelow C, Reed G, Moser F, et al. Natural history of silent infarct in children with sickle cell anemia (HBSS) [abstract]. Blood. 1999;94:419.
4. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65:461-471.
5. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 1991;28:213-219.
6. Gaston M, Rosse W. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982;4:197-201.
7. Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol. 1995:2:103-108.
8. Powars DR. Natural history of sickle cell disease - the first ten years. Semin Hematol. 1975;12:267-285.
9. Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol. 1994;45:279-282.
10. Sarnaik SA, Ballas SK. Molecular characteristics of pediatric patients with sickle cell anemia and stroke. Am J Hematol. 2001;67:179-182.
11. Neonato MG, Guilloud-Bataille M, Beauvais P, et al. Acute clinical events in 299 homozygous sickle cell patients living in France: French Study Group on Sickle Cell Disease. Eur J Haematol. 2000;65:155-164.
12. Adams JH. Cerebral infarction - its pathogenesis and interpretation. J Pathol. 1989;157:281-282.
13. Inoue T, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Analysis of class II genes of human leukocyte antigen in patients with Moyamoya disease. Clin Neurol Neurosurg. 1997;99:S234-S237.
14. Walsh LE, Garg BP. Ischemic strokes in children. Indian J Pediatr. 1997;64:613-623.
15. Rasmussen TE, Hallett JW Jr, Tazelaar HD, et al. Human leukocyte antigen class II immune response genes, female gender, and cigarette smoking as risk and modulating factors in abdominal aortic aneurysms. J Vasc Surg. 2002;35:988-993.
16. Dahlen GH, Slunga L, Holmlund G, Lango A, Lindblom B. Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease. Eur J Immunogenet. 1993;20:95-102.
17. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
18. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96:2451-2459.
19. Styles L, Hoppe C, Klitz W, Vichinsky E, Lubin B, Trachtenberg E. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood. 1999;95:3562-3567.
20. Gaston M, Smith J, Gallagher D, et al. Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials. 1987;8:131S-140S.
21. Farber MD, Koshy M, Kinney TR. Cooperative Study of Sickle Cell Disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis. 1985;38:495-505.
22. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease [see comments]. Am J Neuroradiol. 1996;17:965-972.
23. Bugawan TL, Apple R, Erlich HA. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens. 1994;44:137-147.
24. Bugawan TL, Apple R, Erlich HA. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens. 1994:44:137-147.
25. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Tissue Antigens. 1997;49:297-321.
26. Sokal R, Rohlf F. Biometry: The Principles and Practice of Statistics in Biological Research. San Francisco, CA: WH Freeman; 1995.
27. Klitz W, Stephens JC, Grote M, Carrington M. Discordant patterns of linkage disequilibrium of the peptide-transporter loci within the HLA class II region. Am J Hum Genet. 1995;57:1436-1444.
28. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001;68:686-699.
29. Dahlen G, Slunga L, Lindblom B. Importance of Lp(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin Genet. 1994;46:46-51.
30. Pavlakis SG, Bello J, Prohovnik I, et al. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol. 1988;23:125-130.
31. Gao X, Nelson GW, Karacki P, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med. 2001;344:1668-1675.
32. Tang J, Costello C, Keet IP, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 1999;15:317-324.